Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

FHS
May 16, 2024
11:47 am

Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled ‘Clinical evaluation of EasyM™ for disease response analysis in newly diagnosed MM patients (NDMM)’.

Updated: ‘Ruthless’ pipeline prioritization, obesity and China: Three takeaways from AstraZeneca’s Q4

LONDON — AstraZeneca on Thursday morning teased its vision on how it could potentially enter the obesity market, as well as its views on further

February 9, 2024

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

The FDA approved belzutifan (Welireg) for previously treated advanced renal cell carcinoma (RCC), the agency announced on Thursday. Belzutifan is indicated for RCC patients with

December 16, 2023

Rula Joins Amazon’s Health Condition Programs to Improve Mental Healthcare Access

What You Should Know: – Rula Health, a behavioral health company focused on improving access to mental healthcare, today announced a collaboration with Amazon Health Services

November 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.